NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 120)
Posted On: 08/25/2023 4:24:35 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very promising drug. Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a highly potent, highly specific drug that is safe to use for the large and underserved population of mild-to-moderate psoriasis patients. BiondVax expects to complete a proof-of-concept trial later this year, followed by human clinical trials,” a recent article reads. “BiondVax CEO Amir Reichman explained that there are currently several treatment options on the market for psoriasis patients, such as, for example, creams and other topical drugs, biologics, and oral drugs for plaque psoriasis patients. However, the topicals are not highly sophisticated drugs, and they come with considerable side effects… As for biologics, they are highly potent, but they are restricted to moderate and severe cases of psoriasis, which accounts for only 15% of patients with psoriasis.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very promising drug. Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a highly potent, highly specific drug that is safe to use for the large and underserved population of mild-to-moderate psoriasis patients. BiondVax expects to complete a proof-of-concept trial later this year, followed by human clinical trials,” a recent article reads. “BiondVax CEO Amir Reichman explained that there are currently several treatment options on the market for psoriasis patients, such as, for example, creams and other topical drugs, biologics, and oral drugs for plaque psoriasis patients. However, the topicals are not highly sophisticated drugs, and they come with considerable side effects… As for biologics, they are highly potent, but they are restricted to moderate and severe cases of psoriasis, which accounts for only 15% of patients with psoriasis.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links
Scroll down for more posts ▼